Integrated transcriptome profiling and network pharmacology analysis revealed that XYS has strong potential for treating NASH-related liver fibrosis through the regulation of signal transducer and activator of transcription 3 (STAT3), nuclear factor kappa B (NFκB), and peroxisome proliferator-activated receptor gamma (PPARγ) signaling and subsequently exerts antifibrotic, anti-inflammatory and metabolic regulatory effects. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.